Eon Labs Receives Final Approval for Nitrofurantoin Monohydrate/Macrocrystals Capsules and Will Begin Shipping Immediately

Business Wire, April 6, 2005

LAKE SUCCESS, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB) announced that it received final approval today of Nitrofurantoin Monohydrate/Macrocrystals 100mg capsules, the generic equivalent to Macrobid(R)* capsules. The Company will begin shipping the product immediately.

Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. For press releases and other company information, visit the Eon Labs, Inc. website at www.eonlabs.com.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

*Macrobid(R) is a registered trademark of Procter & Gamble which is not affiliated with Eon Labs, Inc.